ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Non-Hodgkin Lymphoma
Lymphoma
Leukemia

Multiple Myeloma trials near Atlanta, GA, USA:

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: mRNA-2808

Phase 1, Phase 2

Moderna
Moderna

Atlanta, Georgia, United States and 9 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Atlanta, Georgia, United States and 48 other locations

characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple...

Enrolling
Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Drug: Cemsidomide
Drug: Dexamethasone

Phase 2

C4 Therapeutics

Atlanta, Georgia, United States and 9 other locations

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045...

Not yet enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Aldesleukin
Biological: AZD4045

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 11 other locations

to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of developi ...

Enrolling
High Risk Smoldering Multiple Myeloma (HR-SMM)
Drug: Linvoseltamab
Drug: Daratumumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Atlanta, Georgia, United States and 1 other location

is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple...

Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: AZD0120

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 35 other locations

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

Atlanta, Georgia, United States and 40 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Carfilzomib

Phase 2

AbbVie
AbbVie

Atlanta, Georgia, United States and 31 other locations

The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...

Active, not recruiting
Multiple Myeloma
Biological: Ixazomib
Drug: Dexamethasone

Phase 2

The Washington University
The Washington University

Atlanta, Georgia, United States and 9 other locations

interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple...

Enrolling
Multiple Myeloma
Biological: AZD0120

Phase 1

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 12 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems